Sun Pharmaceutical Industries continues to strike deals to expand market access and availability of its lead psoriasis asset Ilumya (tildrakizumab). India’s top-ranked biopharma sealed an exclusive licensing and distribution agreement on 15 June for Ilumya with Hikma Pharmaceuticals for the Middle East and North Africa (MENA) region.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?